Thursday, July 9, 2026

pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL

COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical is a pharma organization headquartered in Stoughton, USA. It trades on NYSE under ticker COLL. Primary therapeutic focus areas include Unstable Angina Pectoris, Gastric Carcinoma, aspirin-exacerb

100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
Status
Public
HQ
100 Technology Center Dr, Stoughton, Massachusetts 02072, US
Employees
617
Programs
29
Drugs
48
Patents
28
Clinical program

Evolocumab

Phase 3 · small molecule · Sars-CoV-2 Infection

Evolocumab for Sars-CoV-2 Infection is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).

← All COLLEGIUM PHARMACEUTICAL, INC projects Phase 3 small molecule completed

Internal code IMPACT-SIRIO 5

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
COLLEGIUM PHARMACEUTICAL, INC
Phase
Phase 3
Modality
small_molecule
Indication
Sars-CoV-2 Infection
Status
completed
Trials
1